Temporal expression pattern of peripheral myelin protein 22 during in vivo and in vitro myelination.
Peripheral myelin protein 22 (PMP22) was initially described as a minor component of peripheral myelin. Mutations affecting the PMP22 gene cause demyelinating neuropathies, supporting a role for the protein in PNS myelination. Furthermore, PMP22 carries the L2/HNK-1 carbohydrate epitope suggesting an adhesion/recognition function. Despite advances in characterizing the PMP22 gene, the specific role(s) of the protein in myelin remains unknown. In this study we determined the temporal expression pattern of PMP22 in comparison to galactocerebroside (GalC) and myelin associated glycoprotein (MAG), early constituents of PNS myelin, and to protein zero (P0) and myelin basic protein (MBP), late components of myelin. In sciatic nerve lysates, PMP22 was detected at postnatal day 3, after MAG, but before MBP expression. The same results were obtained in cocultures of dorsal root ganglion neurons and Schwann cells (SCs). Low levels of PMP22 were found in early, anti-MAG and anti-GalC immunoreactive, myelinating cocultures. However, PMP22 could only be detected in the SC plasma membrane after basal lamina formation. In long-term myelinating cocultures PMP22 levels continued to increase and the protein was found in anti-P0 and anti-MBP immunoreactive myelin segments. Furthermore, PMP22, MBP, and P0 protein levels were greatly enhanced by progesterone treatment of the cocultures. The highest levels of PMP22 expression were associated with late stages of myelination; however the presence of the protein in nonmyelinating SCs and in SCs commencing myelination supports multiple roles for PMP22 in peripheral nerve biology.
Department of Neurobiology, Stanford University School of Medicine, California 94305, USA. notterpe@cmgm.stanford.edu
L
L
Notterpek
G J
GJ
Snipes
E M
EM
Shooter
D000818:Animals; D000831:Animals, Newborn; D002478:Cells, Cultured; D005699:Galactosylceramides / Q000096:biosynthesis*; D004676:Myelin Basic Protein / Q000096:biosynthesis / Q000187:drug effects; D018993:Myelin P0 Protein / Q000096:biosynthesis / Q000187:drug effects; D009185:Myelin Proteins / Q000096:biosynthesis* / Q000187:drug effects; D009186:Myelin Sheath / Q000502:physiology*; D018992:Myelin-Associated Glycoprotein / Q000096:biosynthesis / Q000187:drug effects; D011374:Progesterone / Q000494:pharmacology; D051381:Rats; D012583:Schwann Cells / Q000502:physiology
D005699:Galactosylceramides; D004676:Myelin Basic Protein; D018993:Myelin P0 Protein; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; C489546:Pmp22 protein, rat; C002454:galactocerebroside; D011374:Progesterone